Study #2023-0647
A phase 1, open-label, multicenter study of INCA033989 administered as a monotherapy or in combination with Ruxolitinib in participants with myeloproliferative neoplasms.
MD Anderson Study Status
Enrolling
Treatment Agent
INCA033989, Ruxolitinib
Description
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloproliferative Neoplasms
Study phase:
Phase I
Physician name:
Lucia Masarova
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.